Amarin’s briefly-held fish oil empire has slipped from its grasp, and now appears gone for good.

A US federal appeals court refused on Thursday to overturn a March ruling that stripped the Irish drugmaker of its patents on the fish oil-based heart drug Vascepa, opening the door for generic alternatives to hit the market. The ruling means that Amarin’s chance of turning an expanded approval from last December into blockbuster revenues has essentially vanished.

Bristol Myers Squibb has gotten another approval from the old Celgene pipeline yesterday, this time for a once low-profile compound.

The FDA green-lighted Onureg, an oral drug previously known as CC-486. It’s chemically known as azacitidine — the same compound that in its IV form, branded as Vidaza, has long been used to treat acute myeloid leukemia and myelodysplastic syndromes. For Bristol Myers, it marks the second major approval since the Celgene merger was completed, after the multiple sclerosis drug Zeposia was OK’d earlier this year.

Congress is turning up the heat on AbbVie $ABBV over its pricing policies.

The House Committee on Oversight and Reform is planning to subpoena the biopharma as part of a 2019 probe into the alleged price-gouging of Humira and Imbruvica, according to a memo released Monday. The move comes after the late Elijah Cummings, who chaired the committee, opened the investigation into a dozen drugmakers over 18 months ago and AbbVie did not provide lawmakers with requested documents.

Following in AstraZeneca’s carbon-reduced footsteps, Novartis announced new sustainability targets on Tuesday, which include plans to neutralize supply chain emissions in the next 10 years.

The Swiss pharma aims to be carbon-neutral in its own operations by 2025, and across its supply chain by 2030. To get there, it says it will reduce absolute emissions by 35% across its value chain, and follow a “dual strategy” to decrease energy and fuel consumption, improve efficiency and adopt renewable energy sources. It audited all major sites for potential improvements.

The docket keeps piling up for Teva.

Late Tuesday, the Justice Department became the latest in a long string of prosecutors to accuse the Israeli drugmaker of malfeasance, charging the company with three counts of conspiring to fix generic drug prices. These new allegations come just a week after Teva $TEVA was sued by New York over its role in the opioid epidemic and by federal prosecutors over its purported scheme to defraud Medicare.

When Kite founder Arie Belldegrun laid out his vision for the new biotech building he and son Dan were building with Tishman Speyer in Seaport, he had an idea for a club-like environment that would bring together scientists and entrepreneurs interested in building drugs and companies.

But then the market took control.

Instead of multiple tenants, Breakthrough Properties got one growing biotech to take all 263,500 square feet of space at The 105.

New updates to the process of assembling China’s latest National Drug Reimbursement List could mean that seven additional PD-(L)1 drugs will be covered by government-sponsored insurance schemes — but likely not without significant discounts.

Developers of therapies approved by the National Medical Products Administration before August 17 will be eligible to apply for inclusion on the list. The deadline also applies to any drug that scored new indications.